SPRINT Share Price Performance
Recent SPRINT News & Updates
No updates
Sprint Bioscience AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.20
- Gross Margin
- 57.87%
- Net Profit Margin
- -33.42%
- Debt/Equity Ratio
- 0%
Sprint Bioscience AB (publ) Competitors
About SPRINT
- Founded
- 2009
- Employees
- 38
- CEO
- WebsiteView website
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Swedish Market Performance
- 7 Days: 1.9%
- 3 Months: 5.5%
- 1 Year: -2.3%
- Year to Date: 1.4%
The market has climbed 1.9% in the last 7 days, lead by the Industrials sector with a gain of 2.1%. The market has been flat overall in the last year. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading